Year: 2018
Type: article
Abstract: Failures in the current paradigm for drug development have resulted in soaring research and development costs and reduced numbers of new drug approvals. Over 90% of new drug programs fail, the majority terminated at the level of Phase 2/3 clinical trials, largely because of efficacy failures or unexplained toxicity. A recent workshop brought together members from research institutions, regulatory agencies, industry, academia, and nongovernmental organizations to discuss how existing programs could be better applied to understanding human biology and improving drug discovery. Recommendations include increased emphasis on human relevance, better access and curation of data, and improved interdisciplinary and international collaboration.
Source: Drug Discovery Today
Authors: Lindsay J. Marshall, Christopher P. Austin, Warren Casey, Suzanne C. Fitzpatrick, Catherine Willett
Institutions: Humane World for Animals, Humane World for Animals International, National Institutes of Health, Office of the Director, National Center for Advancing Translational Sciences, National Institute of Environmental Health Sciences, Center for Food Safety and Applied Nutrition, United States Food and Drug Administration
Language: English
Subfield: Small Animals
Field: Veterinary
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,720
Funders: GlaxoSmithKline, Johns Hopkins University, Humane Society International, National Institute for Health and Care Research, Imperial College London, National Institutes of Health, Defense Advanced Research Projects Agency, Genentech, Novartis Pharma, National Institute of Mental Health, National Human Genome Research Institute, National Cancer Institute, National Center for Advancing Translational Sciences
OpenAlex ID: W2807046572